Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy

An Eastern Cooperative Oncology Group trial (PA286)

Avi Israel Einzig, Donna Neuberg, Peter H. Wiernik, Louise B. Grochow, Guillermo Ramirez, Peter J. O'Dwyer, Nicholas J. Petrelli

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.

Original languageEnglish (US)
Pages (from-to)750-754
Number of pages5
JournalAmerican Journal of Therapeutics
Volume3
Issue number11
DOIs
StatePublished - Jan 1 1996

Fingerprint

Paclitaxel
Rectum
Colonic Neoplasms
Colon
Adenocarcinoma
Drug Therapy
Neutropenia

Keywords

  • colon cancer
  • paclitaxel (Taxol)

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy : An Eastern Cooperative Oncology Group trial (PA286). / Einzig, Avi Israel; Neuberg, Donna; Wiernik, Peter H.; Grochow, Louise B.; Ramirez, Guillermo; O'Dwyer, Peter J.; Petrelli, Nicholas J.

In: American Journal of Therapeutics, Vol. 3, No. 11, 01.01.1996, p. 750-754.

Research output: Contribution to journalArticle

Einzig, Avi Israel ; Neuberg, Donna ; Wiernik, Peter H. ; Grochow, Louise B. ; Ramirez, Guillermo ; O'Dwyer, Peter J. ; Petrelli, Nicholas J. / Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy : An Eastern Cooperative Oncology Group trial (PA286). In: American Journal of Therapeutics. 1996 ; Vol. 3, No. 11. pp. 750-754.
@article{1eb578dc5be644ffb22123f7f498ed01,
title = "Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An Eastern Cooperative Oncology Group trial (PA286)",
abstract = "Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.",
keywords = "colon cancer, paclitaxel (Taxol)",
author = "Einzig, {Avi Israel} and Donna Neuberg and Wiernik, {Peter H.} and Grochow, {Louise B.} and Guillermo Ramirez and O'Dwyer, {Peter J.} and Petrelli, {Nicholas J.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1097/00045391-199611000-00003",
language = "English (US)",
volume = "3",
pages = "750--754",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy

T2 - An Eastern Cooperative Oncology Group trial (PA286)

AU - Einzig, Avi Israel

AU - Neuberg, Donna

AU - Wiernik, Peter H.

AU - Grochow, Louise B.

AU - Ramirez, Guillermo

AU - O'Dwyer, Peter J.

AU - Petrelli, Nicholas J.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.

AB - Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxicity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.

KW - colon cancer

KW - paclitaxel (Taxol)

UR - http://www.scopus.com/inward/record.url?scp=0030432043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030432043&partnerID=8YFLogxK

U2 - 10.1097/00045391-199611000-00003

DO - 10.1097/00045391-199611000-00003

M3 - Article

VL - 3

SP - 750

EP - 754

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 11

ER -